SpyGlass Pharma

Historical price data

SpyGlass Pharma is a clinical-stage company with a mission to revolutionize ophthalmologic care by integrating long-acting glaucoma therapy into standard cataract surgery, thereby eliminating patient non-adherence to topical drops. Its core achievement is the development of the BIM-IOL System, a combination product delivering bimatoprost for multi-year intraocular pressure control, which has advanced to Phase 3 clinical trials. The company's strategy leverages established surgical workflows and a well-validated drug to address a large, dual-diagnosis patient population, positioning it to capture significant value in the glaucoma and cataract surgery markets.

Proprietary BIM-IOL System integrating sustained-release, non-bioerodible polymer drug-eluting pads with a standard monofocal intraocular lens for multi-year delivery of therapeutics directly within the eye.

Competition includes MIGS devices (Alcon, Glaukos), sustained-release pharmaceuticals (AbbVie's Durysta), and other drug-eluting IOLs in development. SpyGlass's first-mover potential in long-duration, IOL-integrated therapy for the cataract surgery cohort is its primary differentiator against both the non-adherent drop standard and procedural competitors.